Versatile LC-MS-Based Workflow with Robust 0.1 ppm Sensitivity for Identifying Residual HCPs in Biotherapeutic Products.

Residual host cell proteins (HCPs) in the drug product can affect product quality, stability, and/or safety. In particular, highly active hydrolytic enzymes at sub-ppm levels can negatively impact the shelf life of drug products but are challenging to identify by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) due to their high dynamic range between HCPs and biotherapeutic proteins. We employed new strategies to address the challenge: (1) native digest at a high protein concentration; (2) sodium deoxycholate added during the reduction step to minimize the inadvertent omission of HCPs observed with native digestion; and (3) solid phase extraction with 50% MeCN elution prior to LC-MS/MS analysis to ensure effective mAb removal. A 50 cm long nanoflow charged surface hybrid column was also packed to allow for higher sample load for increased sensitivity. Our workflow has increased the sensitivity for HCP identification by 10- to 100-fold over previous reports and showed the robustness as low as 0.1 ppm for identifying HCPs (34.5 to 66.2 kDa MW). The method capability was further confirmed by consistently identifying >85% of 48 UPS-1 proteins (0.10 to 1.34 ppm, 6.3 to 82.9 kDa MW) in a monoclonal antibody (mAb) and the largest number (746) of mouse proteins from NIST mAb reported to date by a single analysis. Our work has filled a significant gap in HCP analysis for detecting and demonstrating HCP clearance, in particular, extremely low-level hydrolases in drug process development.

[1]  S. Wohlrab,et al.  Identification and Characterization of Polysorbate-Degrading Enzymes in a Monoclonal Antibody Formulation. , 2021, Journal of pharmaceutical sciences.

[2]  R. Molden,et al.  Toward unbiased identification and comparative quantification of host cell protein impurities by automated iterative LC-MS/MS (HCP-AIMS) for therapeutic protein development. , 2021, Journal of pharmaceutical and biomedical analysis.

[3]  S. Nie,et al.  Simple and Sensitive Method for Deep Profiling of Host Cell Proteins in Therapeutic Antibodies by Combining Ultra-Low Trypsin Concentration Digestion, Long Chromatographic Gradients, and BoxCar Mass Spectrometry Acquisition. , 2021, Analytical chemistry.

[4]  Inn H. Yuk,et al.  High-Throughput, Fluorescence-Based Esterase Activity Assay for Assessing Polysorbate Degradation Risk during Biopharmaceutical Development , 2021, Pharmaceutical Research.

[5]  D. Michels,et al.  Fast, Robust and Sensitive Identification of Residual Host Cell Proteins in Recombinant Monoclonal Antibodies using Sodium Deoxycholate Assisted Digestion. , 2020, Analytical chemistry.

[6]  Ning Li,et al.  Rapid Polysorbate 80 Degradation by Liver Carboxylesterase in a Monoclonal Antibody Formulated Drug Substance at Early Stage Development. , 2020, Journal of pharmaceutical sciences.

[7]  F. Duffieux,et al.  Improving the analytical toolbox to investigate copurifying host cell proteins presence: N‐(4)‐(β‐acetylglucosaminyl)‐ l‐asparaginase case study , 2020, Biotechnology and bioengineering.

[8]  Ning Li,et al.  A Combination of FAIMS, Protein A Depletion, and Native Digest Conditions Enables Deep Proteomic Profiling of Host Cell Proteins in Monoclonal Antibodies. , 2020, Analytical chemistry.

[9]  Thomas R. Slaney,et al.  Enhancing Host-Cell Protein Detection in Protein Therapeutics Using HILIC Enrichment and Proteomic Analysis. , 2020, Analytical chemistry.

[10]  Ning Li,et al.  Improved host cell protein analysis in monoclonal antibody products through molecular weight cutoff enrichment. , 2020, Analytical chemistry.

[11]  C. Zamiri,et al.  A Rapid High-Sensitivity Reversed -Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics. , 2019, Journal of pharmaceutical sciences.

[12]  S. Wohlrab,et al.  Evaluation of peptide fractionation and native digestion as two novel sample preparation workflows to improve HCP characterization by LC-MS/MS. , 2019, Analytical chemistry.

[13]  Tobias Graf,et al.  Monitoring polysorbate hydrolysis in biopharmaceuticals using a QC-ready free fatty acid quantification method. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  D. Michels,et al.  A 2D LC-MS/MS Strategy for Reliable Detection of 10-ppm Level Residual Host Cell Proteins in Therapeutic Antibodies. , 2018, Analytical chemistry.

[15]  Kelvin H. Lee,et al.  Knockout of a difficult‐to‐remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations , 2017, Biotechnology and bioengineering.

[16]  Lihua Huang,et al.  A Novel Sample Preparation for Shotgun Proteomics Characterization of HCPs in Antibodies. , 2017, Analytical chemistry.

[17]  Abraham M Lenhoff,et al.  Host cell protein impurities in chromatographic polishing steps for monoclonal antibody purification , 2016, Biotechnology and bioengineering.

[18]  Lihua Huang,et al.  Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A2 Isomer X1 in Monoclonal Antibody Formulations. , 2016, Journal of pharmaceutical sciences.

[19]  Katherine D Taylor,et al.  Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles. , 2016, Journal of pharmaceutical sciences.

[20]  Weibin Chen,et al.  Enhanced Detection of Low-Abundance Host Cell Protein Impurities in High-Purity Monoclonal Antibodies Down to 1 ppm Using Ion Mobility Mass Spectrometry Coupled with Multidimensional Liquid Chromatography. , 2015, Analytical chemistry.

[21]  A. Farrell,et al.  Quantitative host cell protein analysis using two dimensional data independent LC-MS(E). , 2015, Analytical chemistry.

[22]  Rui Nian,et al.  Non-immunospecific association of immunoglobulin G with chromatin during elution from protein A inflates host contamination, aggregate content, and antibody loss. , 2015, Journal of chromatography. A.

[23]  V. Farutin,et al.  Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis , 2015, mAbs.

[24]  J. Zhu-Shimoni,et al.  Host cell protein testing by ELISAs and the use of orthogonal methods , 2014, Biotechnology and bioengineering.

[25]  Abraham M Lenhoff,et al.  Identification and characterization of host cell protein product‐associated impurities in monoclonal antibody bioprocessing , 2014, Biotechnology and bioengineering.

[26]  Alois Jungbauer,et al.  Harnessing Candida tenuis and Pichia stipitis in whole‐cell bioreductions of o‐chloroacetophenone: Stereoselectivity, cell activity, in situ substrate supply and product removal , 2013, Biotechnology journal.

[27]  B. Nogal,et al.  Select host cell proteins coelute with monoclonal antibodies in protein a chromatography , 2012, Biotechnology progress.

[28]  Shujun Bai,et al.  Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. , 2011, Biotechnology and bioengineering.

[29]  P. Hinckley,et al.  Host cell protein clearance during protein a chromatography: Development of an improved column wash step , 2008, Biotechnology progress.

[30]  Michael Rubacha,et al.  Demonstration of Robust Host Cell Protein Clearance in Biopharmaceutical Downstream Processes , 2008, Biotechnology progress.

[31]  S. Fischer,et al.  Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material , 2016, The AAPS Journal.